Cover Image
市場調查報告書

甲鈷胺的中國市場:2010∼2019年

Investigation Report on China Methylcobalamin Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 353342
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
甲鈷胺的中國市場:2010∼2019年 Investigation Report on China Methylcobalamin Market, 2010-2019
出版日期: 2016年02月29日 內容資訊: 英文 20 Pages
簡介

甲鈷胺是維他命B12衍生物,用於末梢神經病變的治療藥。該藥物,刺激神經內部的核酸和蛋白質,代謝作用,促進DNA和RNA,卵磷脂脂質的合成,加快損傷的神經組織的再生。1980年代中間由Eisai開發,中國自1996年上市。中國國內的甲鈷胺的市場規模,2005年是2億人民幣以下,2014年為4億4100萬人民幣,以12.32%年複合成長率 (CAGR) 的成長。

本報告提供中國的甲鈷胺的市場相關分析,關於甲鈷胺的特徵和認證情形,整體市場規模,各企業、各劑型的市場佔有率,價格趨勢,主要製造商簡介,今後的市場成長預測等調查評估。

第1章 甲鈷胺的相關概念

  • 適應症
  • 全球市場的銷售情形

第2章 中國國內的甲鈷胺市場簡介

  • 中國國內的甲鈷胺的專利申請、核準情況
  • 主要製造商
  • 市場規模

第3章 中國國內的甲鈷胺銷售額分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 甲鈷胺的主要廠商的市場佔有率 (過去5年份)

  • 市場佔有率 (以金額為準)
  • 市場佔有率 (以數量為準)

第5章 中國國內的甲鈷胺的劑型 (過去5年份)

  • 各劑型的市場佔有率 (以金額為準)
  • 各劑型的市場佔有率 (以數量為準)

第6章 中國的醫院的甲鈷胺的參照價格

  • North China Pharmaceutical Group Corp. (NCPC)
  • Eisai (Suzhou) Pharmaceutical Co., Ltd.
  • Eisai (日本)
  • Nanjing Hailing Pharmaceutical Co., Ltd.
  • Jiangsu Sihuan Bioengineering Co., Ltd.

第7章 中國國內的甲鈷胺的主要製造商 (過去5年份)

  • North China Pharmaceutical Group Corp. (NCPC)
  • Eisai (Suzhou) Pharmaceutical Co., Ltd.
  • Eisai (日本)
  • Nanjing Hailing Pharmaceutical Co., Ltd.
  • Jiangsu Sihuan Bioengineering Co., Ltd.

第8章 中國國內的甲鈷胺市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭模式的預測

圖表一覽

目錄
Product Code: 1602321

Peripheral neuropathy is a syndrome, which is a single or any combination form of sensory loss, muscle weakness and atrophy, decreased tendon reflex and vasomotion symptoms. The factors which lead to peripheral neuropathy are that the damage of single neural limitation is a common cause of trauma, while multiple single neuropathy occurs secondary to collagen vascular disease; Multiple neuropathy may be caused by toxins, toxic substances, nutrition deficiency, metabolic disease and malignant tumors.

Methylcobalamin, derivative of Vitamin B12, is active Vitamin B12 and the therapeutic drug of peripheral neuropathy. It can promote intraneural nucleic acid, protein and metabolism, facilitate the synthesis of DNA,RNA as well as the synthesis of lecithin lipid, which is the main component of myelin sheath, and accelerate to restore the damaged nerve tissue to improve the transformation of nerve tissue and the disturbance of metabolism. In addition, it also works on restraining unusual exciting conduction of nerve tissue.

Methylcobalamin,. whose trade name is mecobalamin, was developed by Eisai Co., Ltd. and put in the market in Japan in the middle of 1980s.In 1996, mecobalamin entered the Chinese market.

Methylcobalamin developed rapidly after entering China. Its annual sales value increased from less than 200 million CNY in 2005 to 441 million CNY in 2014, with CAGR of 12.32%. It had broad market demand in China. Eisai (Suzhou) Pharmaceutical Co., Ltd, Eisai Co., Ltd. (Japan), Jiangsu Sihuan Bioengineering Co., Ltd, Nanjing Hailing Pharmaceutical Co., Ltd. and NCPC occupy large market share, among which Eisai (Suzhou) Pharmaceutical Co., Ltd occupies most, whose annual market share of sales value was over 40% in 2014.

It is predicted that in next few years, the incidence of peripheral neuropathy in China will gradually rise, making the market scale of methylcobalamin continue to increase.

Through this report, readers can get the followings and more information:

  • Market scale of Methylcobalamin in China
  • Market Competitive pattern of Methylcobalamin in China
  • Sales price of Methylcobalamin made by different enterprises in China
  • Market outlook of Methylcobalamin in China

The author recommends the following people to purchase this report:

  • Production enterprises of methylcobalamin drugs
  • Investors/research institutions focusing on Chinese pharmaceutical market

If interested in Chinese pharmaceutical market, you can contact CRI for customized survey service.

Table of Contents

1. Related Concepts of Methylcobalamin

  • 1.1. Indications
  • 1.2. Sales Status in Global Market

2. Market Profile of Methylcobalamin in China

  • 2.1. Patent and Approval Information of Methylcobalamin in China
  • 2.2. Major Manufacturing Enterprises
  • 2.3. Market Scale

3. Survey on Methylcobalamin Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Methylcobalamin Production Enterprises in China, 2010-2014

  • 4.1. Market Share of Producing Businesses by Sales Value
  • 4.2. Market Share of Producing Businesses by Sales Volume

5. Survey on Dosage Forms of Methylcobalamin in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Sales Price of Methylcobalamin in Chinese Hospitals in 2014

  • 6.1. North China Pharmaceutical Group Corp. (NCPC)
  • 6.2. Eisai (Suzhou) Pharmaceutical Co., Ltd.
  • 6.3. Eisai Co., Ltd. (Japan)
  • 6.4. Nanjing Hailing Pharmaceutical Co., Ltd.
  • 6.5. Jiangsu Sihuan Bioengineering Co., Ltd.

7. Major Production Enterprises of Methylcobalamin in Chinese Market, 2010-2014

  • 7.1. North China Pharmaceutical Group Corp. (NCPC)
  • 7.2. Eisai (Suzhou) Pharmaceutical Co., Ltd.
  • 7.3. Eisai Co., Ltd. (Japan)
  • 7.4. Nanjing Hailing Pharmaceutical Co., Ltd.
  • 7.5. Jiangsu Sihuan Bioengineering Co., Ltd.

8. Market Outlook of Methylcobalamin in China, 2015-2019

  • 8.1. Prediction of Market Size
  • 8.2. Prediction of Competitive Pattern

Selected Charts

  • Chart Patent Status of Methylcobalamin in China
  • Chart Approval Information of Methylcobalamin in China
  • Chart Sales Status of Methylcobalamin in China
  • Chart Sales Value of Methylcobalamin in China, 2010-2014
  • Chart Sales Value of Methylcobalamin in Some Regions of China, 2010-2014
  • Chart Sales Volume of Methylcobalamin in China, 2010-2014
  • Chart Sales Volume of Methylcobalamin in Some Regions of China, 2010-2014
  • Market Share of Corporations of TOP5 Methylcobalamin Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Methylcobalamin Produced by Eisai (Suzhou) in China, 2010-2014
  • Chart Sales Value and Market Share of Methylcobalamin Produced by Eisai (Japan) in China, 2010-2014
  • Chart Sales Value and Market Share of Methylcobalamin Produced by Jiangsu Sihuan in China, 2010-2014
  • Chart Sales Value and Market Share of Methylcobalamin Produced by Nanjing Hailing in China, 2010-2014
  • Chart Sales Value and Market Share of Methylcobalamin Produced by NCPC in China, 2010-2014
  • Chart Sales Value and Market Share of Methylcobalamin Injection in China, 2010-2014
  • Chart Sales Value and Market Share of Methylcobalamin Tablet in China, 2010-2014
  • Chart Sales Value and Market Share of Methylcobalamin Capsule in China, 2010-2014
  • Chart Sales Price of Methylcobalamin Produced by NCPC in Some Chinese Cities in 2014
  • Chart Sales Price of Methylcobalamin Produced by Eisai (Suzhou) in Some Chinese Cities in 2014
  • Chart Sales Price of Methylcobalamin Produced by Eisai (Japan) in Some Chinese Cities in 2014
  • Chart Sales Price of Methylcobalamin Produced by Nanjing Hailing Pharmaceutical Co., Ltd. in Some Chinese Cities in 2014
  • Chart Sales Price of Methylcobalamin Produced by Jiangsu Sihuan Bioengineering Co., Ltd. in Some Chinese Cities in 2014
Back to Top